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characteristics (CD34, CD3, CD19, NK, DC1and DC2 cell dose).
Survival curve analysis by a log rank test revealed that the low DC2
group had a signiﬁcant risk of developing acute and chronic
GVHD (P0.000 for both). These results suggest that the DC2
count in the peripheral blood on day-28 is a strong predictor for
development of GVHD in recipients of PBSC in a matched related
allogeneic SCT.
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A CDNA-BASED ASSAY FOR DONOR-CHIMERISM ANALYSIS OF EPIDER-
MAL LANGERHANS CELLS
Bakhtiar, S.1, Bender, K.2, Schmitt, T.1, Moench, C.3, Konur, A.1,
Huber, C.1, Herr, W.1, Meyer, R.G.1 1Johannes Gutenberg University,
Mainz, Germany; 2Johannes Gutenberg University, Department of
Legal Medicine, Mainz, Germany; 3Johannes Gutenberg University,
Department of Transplantation Surgery, Mainz, Germany.
Early acute GVHD of the skin frequently occurs in patients after
allogeneic hematopoietic stem cell transplantation. T cell depletion
sufﬁciently reduces incidence and severity, but does not completely
prevent skin GVHD which then leads to a prolonged need for im-
munosuppressive medication. The activation of donor T cells by
residing host antigen presenting cells such as epidermal Langerhans
cells (LCs) plays a central role in the initiation of acute GVHD. The
absence of donor T cells after depletion delays the switch of LCs from
host to donor origin in mice. We and others have provided evidence
for a delayed switch in LC chimerism after T cell depleted reduced
intensity stem cell transplantation in humans. However, most assays
used so far either depend on the detection of the Y-chromosome in
skin sections of sex-mismatched transplants. In an attempt to set up a
sensitive assay of general applicability, we combined the detection of
donor chimerism and tissue speciﬁc markers in a single multiplex
PCR. We established RT-PCRs for 10 different constitutively ex-
pressed genes containing single nucleotide polymorphisms (SNPs)
inside their coding regions. These PCRs were combined in a single
multiplex PCR and the SNPs were analyzed by the primer extension
method (minisequencing) and separated by capillary electrophoresis.
We tested this approach on PBMCs of 10 patients and their HLA-
matched sibling donors. The assay distinguished all pairs in 1 to 6 out
of 10 systems. In a subsequent step, the 10plex PCR was combined
with the tissue speciﬁc markers langerin for LCs and cytokeratin 10 to
distinguish LCs from keratinocytes. The expression of langerin and
cytokeratin 10 was detected using gene-speciﬁc probes in the same
minisequencing reaction used for the detection of SNPs. The result-
ing 12plex assay distinguished sibling donors from the patients with
the same speciﬁcity and, in the same reaction, detected Langerin as
well as cytokeratin 10 in puriﬁed LCs and keratinocytes, respectively.
In summary, we established a sensitive assay allowing simultaneous
detection of donor chimerism together with the tissue speciﬁcity of
isolated LCs that is independent of sex-mismatched donors. The
addition of further tissue speciﬁc markers might allow performing
chimerism studies on other tissue resident antigen presenting cells.
The use of a cDNA-based assay might also allow combining chimer-
ism analysis with activation- and maturation speciﬁc markers in a
single assay.
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SELECTIVE DEPLETION OF ALLOREACTING T CELLS BY TH9402-BASED
PHOTODEPLETION AS A TRANSLATIONAL STRATEGY FOR GVHD CON-
TROL IN HLA-MISMATCHED AND MATCHED DONOR-RECIPIENT PAIRS
Mielke, S.1, Nunes, R.1, Rezvani, K.1, Fellowes, V.S.2, Fan, Y.2,
Scotto, C.3, Solomon, S.P.1, Read, E.J.2, Barrett, A.J.1 1Stem Cell
Allotransplantation Section, Hematology Branch, NHLBI, NIH, Be-
thesda, MD; 2Cell Processing Section, Department of Transfusion Med-
icine, NIH, Bethesda, MD; 3Celmed Biosciences Inc., Saint-Laurent,
QC, Canada.
Selective depletion (SD) is a strategy to eliminate host-reactive
donor lymphocytes from blood stem cell allografts to prevent GVHD
and maintain GVL-effects. We investigated a photodepletion (PD)
process, whereby allo-activated donor cells are labeled with a photo-
sensitizing rhodamine-based dye, 4,5-dibromorhodamide 123
(TH9402), and exposed to visible light, which preferentially elimi-
nates allo-activated dye-retaining cells. Stimulator cells were prepared
from recipient-derived leukapheresis mononuclear cells (MNCs) and
cultured using anti-CD3 and 100 IU IL-2/ml. Responder cells (leu-
kapheresis MNCs) from 3 random HLA-mismatched volunteers and
3 HLA-matched sibling donors were cocultured 1:1 with irradiated
stimulators for 3 days. Cultured cells were incubated with 7.5 	M
TH9402, followed by dye-extrusion and exposure to 5 Joule light
energy in the PD light source (Celmed Bioscience Inc., Canada) at
510
6
cells/ml in FEP plastic bags. Depletion efﬁcacy was studied by
mixed lymphocyte reactions (MLR) in mismatched pairs and by help-
er-T-lymphocyte precursor (HTLp) frequency assay in matched
pairs. All six clinical-scale experiments provided sufﬁcient reduction of
allo-reactivity and retention of third party responses as measured
against a pool of 5 donors. In mismatched pairs mean reduction of
allo-reactivity was 703-fold ( 141) when compared to unmanipu-
lated donors. Third-party responses were maintained, with a mean
reduction of only 1.3  0.15-fold. In matched pairs alloreactivity was
reduced below the “GVHD-threshold” of 1/100.000 whilst third
party responses remained above 1/10.000 precursors. This establishes
a clinical scale PD process capable of highly efﬁcient removal of
alloreactive lymphocytes from mismatched and matched MLRs while
maintaining desirable third party responses. As PD targets activation-
based changes in MDR-1 that result in an altered dye efﬂux, the
mechanism of action is distinct from surface-marker-based allodeple-
tion (e.g. CD69, CD25). Thus, PD may overcome instability of
activation-based surface marker expression resulting in more consis-
tent and effective depletion. This approach will now be tested in a
clinical SD trial.
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PHARMACOKINETICS (PK) OF MYCOPHENOLATE MOFETIL (MMF) IN
PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT (ALLOSCT) RECIP-
IENTS
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Cairo, M.S.2,3,4 1Department of Pathology, NewYork-Presbyterian, Co-
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MMF PK in children may impact on the incidence of moderate/
severe acute GVHD following AlloSCT (Osunkwo/Cairo et al,
BBMT 2004). The objective of this study is to evaluate effects of age
on the PK of MMF in pediatric AlloSCT recipients. From 1/04 –
8/06 we enrolled 31 pediatric AlloSCT with 27 being evaluable: mean
age 8.5 yrs; wt 34.3 kg; M:F12:15; NBL PR (n3), SCD (n3),
AML (CR1 [n4], CR2 [n1], CR3 [n1], relapsed/induction fail-
ure [n3]), SAA (n5), CML CP (n1), ALL (CR1 [n1], CR2
[n2], CR3 [n1]), HD CR2 (n1), ALCL refractory (n1); donor
sources: MFD (6/6 PBSC [n7], 6/6 BM [n3], 5/6 PBSC [n3]),
6/6 related CB (n1), UCB (6/6 [n2], 5/6 [n3], 4/6 [n7]), and
8/10MUDPBSC (n1). Cohort 1 [ 6 yrs] (n8); 2 [6-12 yrs of age]
(n9); 3 [12–16 yrs] (n10). GVHD prophylaxis included tacrolimus
(onDay –1 or 1st day of conditioning to maintain concentrations 5-20
ng/mL) and MMF (900 mg/m2 IV Q6H starting on Day 1, then
converted to PO [same dose] after Day14). Serum samples forMPA
were drawn on Day 1, 7, and 14 at hour 0, 0.5, 1, 2, 3, 4, and 6
post-dose. MPA plasma concentrations were determined by reverse-
phase HPLC.MMF dose was adjusted to maintainMPA trough 1-3.5
mg/L. The mean CD34 cell dose/kg 27.5105, TNC dose/kg
50.3107. Time to neutrophil (ANC  500/mm3 x 2 d) and platelet
engraftment (untransfused count  20K x 7 d) was 22 d and 36 d,
respectively. Mean f/u was 448 d. Mean MPA PK on Day 14:
Cmax17.6 mg/L, Tmax1.82 h, total MPA trough0.85 mg/L,
AUC0-639.4 mg  hr/L, T1/21.3 h, Vd1.5 L/kg, and CL1.2
L/kg/h at a mean MMF dose of 1056 mg/m2 IV Q6H. Age cohorts
are shown in Table 1. Incidence of GI adverse events attributable to
MMF was 59% (nausea/vomiting [n13], diarrhea [n8], abdominal
pain [n3], pneumatosis intestinalis [n1], gastritis/colitis [n2]).
Kaplan-Meier probability of grade II-IV aGVHD following related
[n14] and unrelated [n13] donors was 60.8% (15/27 evaluable pts),
cGVHD was 25.2% (5/22 evaluable pts) and 1 year OS was 64.4%
(CI: 45.6-83.1%). In comparison to MMF PK in adult AlloSCT pts
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